Skip to main content

Table 1 Characteristics of patients and therapeutic effect in the combined treatment group and the aumolertinib monotherapy group

From: Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence

 

Combined treatment (n = 15)

Aumolertinib (n = 50)

P-value

N (%)

N (%)

Gender

p = 0.25

Male

9 (60%)

21 (42%)

 

Female

6 (40%)

29 (58%)

 

Age

p = 0.91

Median Age

65

67

 

 < 70 years

9 (60%)

29 (58%)

 

 ≥ 70 years

6 (40%)

21 (42%)

 

Stage prior therapy

p = 0.77

Stage II

0

2 (4%)

 

Stage III

3 (20%)

10 (20%)

 

Stage IV

12 (80%)

38 (76%)

 

EGFR

p = 0.57

Mutant

15 (100%)

50 (100%)

 

Del19

9 (60%)

25 (50%)

 

L858R

6 (40%)

25 (50%)

 

Tumor response

p = 0.04

Complete response (CR)

0 (0%)

0 (0%)

 

Partial response (PR)

14 (93.3%)

32 (64%)

 

Stable disease (SD)

1 (6.7%)

14 (28%)

 

Progressive disease (PD)

0 (0%)

4 (8%)

Â